Research Conducted at Dana-Farber Cancer Institute Has Provided New Information about Endometrial Cancer (A Phase Ii, Two-stage Study of Letrozole and Abemaciclib In Estrogen Receptor-positive Recurrent Endometrial Cancer).

Předmět:	ENDOMETRIAL cancer LETROZOLE DNA-binding proteins ESTROGEN receptors TRANSCRIPTION factors
Zdroj:	Women's Health Weekly; 4/11/2023, p870-870, 1p
Abstrakt:	At the data cutoff date (December 03, 2021), 30 patients (28 with endometrioid EC) initiated protocol therapy; 15 (50%) patients had prior hormonal therapy. Keywords: Boston; State:Massachusetts; United States; North and Central America; Abemaciclib Therapy; Antineoplastics; Aromatase Inhibitors; Cancer; DNA-Binding Proteins; Drugs and Therapies; Endometrial Cancer; Enzymes and Coenzymes; Estrogen Receptors; Gynecology; Health and Medicine; Hormones; Kinase; Kinase Inhibitors; Letrozole Therapy; Oncology; Pharmaceuticals; Proteins; Steroid Receptors; Therapy; Transcription Factors; Women's Health EN Boston State:Massachusetts United States North and Central America Abemaciclib Therapy Antineoplastics Aromatase Inhibitors Cancer DNA-Binding Proteins Drugs and Therapies Endometrial Cancer Enzymes and Coenzymes Estrogen Receptors Gynecology Health and Medicine Hormones Kinase Kinase Inhibitors Letrozole Therapy Oncology Pharmaceuticals Proteins Steroid Receptors Therapy Transcription Factors Women's Health 870 870 1 04/10/23 20230411 NES 230411 2023 APR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Current study results on Oncology - Endometrial Cancer have been published. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu